Ramaswamy Karthik
University of Massachusetts Medical School, Worcester, MA, USA.
Card Electrophysiol Rev. 2003 Sep;7(3):229-32. doi: 10.1023/B:CEPR.0000012388.85901.1c.
Atrial fibrillation (AF) is present in a significant number of patients with heart failure (HF) caused by left ventricular systolic dysfunction and is associated with increased morbidity and mortality. The deleterious interaction of AF and HF is mediated through a number of mechanisms including hemodynamic alterations and activation of the sympathetic nervous system. Beta-blockers have been shown to improve symptoms and survival in patients with HF. In addition, beta-blockers have been used in patients with AF, primarily for rate control. A retrospective analysis of the U.S. Carvedilol Heart Failure Trial demonstrated that carvedilol improves outcomes in the high-risk subgroup of patients with HF and concomitant AF.
心房颤动（AF）在大量由左心室收缩功能障碍引起的心力衰竭（HF）患者中存在，并且与发病率和死亡率增加相关。AF和HF的有害相互作用通过多种机制介导，包括血流动力学改变和交感神经系统激活。β受体阻滞剂已被证明可改善HF患者的症状和生存率。此外，β受体阻滞剂已用于AF患者，主要用于控制心率。对美国卡维地洛心力衰竭试验的回顾性分析表明，卡维地洛可改善HF合并AF的高危亚组患者的预后。
